Test Code TTIGS Tetanus Toxoid IgG Antibody, Serum
Reporting Name
Tetanus Toxoid IgG Ab, SUseful For
Assessing antibody response to the tetanus toxoid vaccine, which should be performed at least 3 weeks after immunization
Aiding in the evaluation of immunodeficiency
Performing Laboratory

Specimen Type
SerumSpecimen Required
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 30 days | |
Frozen | 30 days |
Reference Values
Vaccinated: Positive (≥0.01 IU/mL)
Unvaccinated: Negative (<0.01 IU/mL)
Day(s) Performed
Monday through Friday
Test Classification
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86317
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
TTIGS | Tetanus Toxoid IgG Ab, S | 53935-3 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
TETG | Tetanus IgG Ab | 33469-8 |
DEXTG | Tetanus IgG Value | 53935-3 |
Clinical Reference
1. Boland Birch T, Bleck TP: Tetanus (Clostridium tetani). In Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2948-2953
2. Gergen PJ, McQuillan GM, Kiely M, et al: A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995 Mar;332(12):761-766
3. Bjorkholm B, Wahl M, Granstrom M, Hagberg L: Immune status and booster effects of low doses of tetanus toxoid in Swedish medical personnel. Scand J Infect Dis. 1994;26(4):471-475
4. Ramsay ME, Corbel MJ, Redhead K, et al: Persistence of antibody after accelerated immunization with diptheria/tetanus/pertussis vaccine. BMJ. 1991 Jun;302(6791):1489-1491
5. Rubin RL, Tang FL, Chan EK, et al: IgG subclasses of anti-tetanus toxoid antibodies in adult and newborn normal subjects and in patients with systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity. J Immunol. 1986 Oct;137(8):2522-2527
6. Simonsen O, Bentzon MW, Heron I: ELISA for the routine determination of antitoxic immunity to tetanus. J Biol Stand. 1986 Jul;14(3):231-239
Method Description
The EuroImmun Anti-Tetanus Toxoid enzyme-linked immunosorbent assay provides a quantitative in vitro assay for detecting human IgG-class antibodies to Tetanus toxoid. The test kit contains reagent wells coated with tetanus toxoid. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labeled anti-human IgG (enzyme conjugate), catalyzing a color reaction.(Package insert: Anti-Tetanus Toxoid ELISA (IgG) Test instruction. EuroImmun US; 08/18/2017)
Report Available
Same day/1 to 4 daysReject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Method Name
Enzyme Immunoassay (EIA)
Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.